Prof. Xu is a senior group leader at the Australian Institute for Bioengineering and Nanotechnology, The University of Queensland. His research focuses on control preparation of layered double hydroxide nanomaterials, calcium phosphate nanoparticles, nanoemulsions, quantum dots, chemosensros and nanosensors, and their applications in biomedicine and agriculture. He has published over 330 peer-reviewed journal papers, conference papers and book chapters. His research has led to many high quality papers published in Nature Plants, Adv Mater, Nano Letters, JACS, Angew Chim Int Ed, Adv Funct Mater, Biomaterials, J Control Release, Chem Mater, Small, Nanoscale, ACS Appl Mater Interface and nanomedicine. Specifically, his publications on layered double hydroxide materials from 2008-2018 rank him in the top #6 among more than 1000 scientists in this research field in terms of the journal paper count. His papers have been cited over 19,395 times with the H-index of 75. He works as Editorial Board Member for six journals, such as Journal of Nanotechnology and Smart Materials, Frontiers in Inorganic Chemistry, Biointerface Research in Applied, and Current Pharmaceutical Design. He also served as reviewers of over 20 journals, including JACS, Biomaterials, Small, Nature Commun, Nanoscale, Adv Functional Mater, Chem Mater, ACS Appl Mater Interface, J Mater Chem B, J Phys Chem B and C.

Dr. Huang focuses on the molecular mechanism of obesity (BAT development and iWAT browning), diabetes (selective and total insulin resistance) and cancer therapy. He has published more than 30 papers (first author or corresponding author) in scientific journals including Nature Communications (3 papers); Advanced Science; Cell Reports; Journal of Biological Chemistry; Developmental Cell. He was awarded Top 1% global reviewer in the field of Clinical Medicine, Molecular Biology & Genetics and Cross-field by Web of Science Group and Publons in 2018 and 2019; He served as a grant reviewer for Nature Science Foundation of China (life science and medicine); He also served as a reviewer for 50 SCI journals and a scientific editor for 10 SCI journals.

He is the Fellow of APS, AVS, IEEE, MRS, HKAES, and HKIE, Chair Professor of Materials Engineering, Department of Physics, Department of Materials Science and Engineering, Department of Biomedical Engineering, City University of Hong Kong. He has authored / co-authored more than 40 book chapters, 2,000 papers in international refereed journals, as well as 1,000 international conference papers including over 150 plenary, keynote, and invited talks, and 15 conference papers received best paper awards. He is a highly cited researcher in materials science from 2016 to 2018, cross-field in 2019 and 2020, materials science in 2021, and cross-field in 2022 according to Web of Science / Clarivate Analytics

He is the Fellow of the American Academy of Microbiology, the Program Director of Viruses and Emerging Pathogens Program, Associate Director of OSU Infectious Diseases Institute, Center for Retrovirus Research, OSU.

He is the Director of the Institute of Medical Microbiology of Fudan University, the Fellow of the American Academy of Microbiology. He has undertaken more than 30 research grants from NIH of the USA, NSFC and other foundations, with a total funding of more than 200 million yuan. He has published 561 SCI papers with 38,311 citations and an h-index of 96 (Google Scholar). Since 2020, he has published 120 SCI papers in high-profile journals, e.g., Lancet, Cell (x2), Nature, Science (x2) and their sister journals (x44), with a total impact factor of 2,600 (average per paper: 21.8). He has served as a Consultant Editor for the Lancet, Associate Editor for Viruses, and Editorial Board Member for Antiviral Res and other 9 SCI journals. He has been granted 25 U.S. patents and 26 Chinese and PCT patents, of which 11 have been successfully licensed out, and several medical products are in the market.

Dr Seifedine Kadry has a bachelor’s degree in 1999 from Lebanese University, MS degree in 2002 from Reims University (France) and EPFL (Lausanne), PhD in 2007 from Blaise Pascal University (France), HDR degree in 2017 from Rouen University. He is a Professor of Data Science at Noroff University College, Norway. At present his research focuses on Data Science, education using technology, system prognostics, stochastic systems, and applied mathematics. He is an ABET program evaluator for computing, and ABET program evaluator for Engineering Tech. He is a Fellow of IET, Fellow of IETE, and Fellow of IACSIT. He is a distinguish speaker of IEEE Computer Society.

Dr. Yutong Zhao graduated from Dalian Medical University in China, and received his PhD from Gifu University School of Medicine in Japan. We conducted his postdoctoral training at the Johns Hopkins University School of Medicine. He started his independent academic career at the University of Chicago, and was promoted to Associate and full professor at the University of Pittsburgh. Currently, Dr. Zhao is a professor of Physiology and Cell Biology at the Ohio State University. His research is focused on molecular regulation of protein stability in lung diseases including lung cancer, lung injury, and pulmonary fibrosis. Dr. Zhao has published more than 125 research articles in peer-reviewed journals including Nature Communication, Molecular Cancer, and Circulation Research etc.

He is the Principal Research Fellow at University of Southampton. Lai has been long engaged in interdisciplinary research focusing on human mobility, environmental changes, and infectious disease transmission dynamics and early warning. He has more than 130 papers published in scientific journals such as Nature, Science, Lancet Infectious Diseases, Nature Medicine, Nature Human Behaviour, BMJ, and Nature Communications. During the COVID-19 pandemic, he has been leading a series of influential studies for understanding the COVID-19 transmission dynamics and intervention effectiveness, using epidemiological and mobility data obtained from different novel ‘big data’ sources. The findings of these studies have been timely shared with the WHO, Africa CDC, Europe CDC, China CDC, among others, for tailoring COVID-19 intervention strategies, and also featured in main media outlets across the world. His studies on exploring how to use mobile phone data for measuring population mobility, migration and dynamics have aroused great interest, being presented in multiple international conferences including the United Nations 5th conferences International Conference on Big Data for Official Statistics.

Dr. Dongdong Wang is a senior scientist at McMaster University. His current research is focused on drug-discovery for cardiovascular disease, NASH, obesity, and diabetes. He has published more than 60 peer-reviewed articles in high prestigious journals such as Nature, Nature Review Endocrinology, Nature Metabolism, Pharmacological reviews, Biotechnology Advances, Seminars in Cancer Biology, and many others. He has co-edited several special issues of scientific journals. Currently he is an editorial board member on several scientific journals and an active reviewer on more than 50 journals.

Dr. Xufeng Chen graduated from the University of Chinese Academy of Science (Shanghai Institute of Biochemistry and Cell Biology, SIBCB), and is now working as an instructor in the New York University Grossman School of Medicine. His research area is focused on understanding the regulation of leukemogenesis and the acquisition of drug resistance in myeloid leukemias, as well as developing novel combinational therapies for circumventing drug resistance to targeted therapies and immunotherapies. In recent years, Dr. Chen has published several SCI papers in high impact journals including Cell, Cancer Discovery, Cell Research, Nature Communications, Cell Report, PNAS, Blood etc. Dr. Chen received the “Leukemia Research Foundation (LRF) Hollis Brownstein Research Grants Program” and the “American Society of Hematology (ASH) Scholar Award”.